# EDGAR Filing Document

**Accession Number:** 0002010788
**File Stem:** 0001641172-25-015782
**Filing Date:** 2025-6
**Character Count:** 5179
**Document Hash:** bf0512c410dfe3fa163660f24e3eca81
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-015782.hdr.sgml**: 20250620

**ACCESSION NUMBER**: 0001641172-25-015782

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250617

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250620

**DATE AS OF CHANGE**: 20250620

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EXOZYMES INC.
- **CENTRAL INDEX KEY:** 0002010788
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 834550057
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42204
- **FILM NUMBER:** 251060430

**BUSINESS ADDRESS:**
- **STREET 1:** 750 ROYAL OAKS DR
- **CITY:** MONROVIA
- **STATE:** CA
- **ZIP:** 91016
- **BUSINESS PHONE:** (626) - 415 - 1488

**MAIL ADDRESS:**
- **STREET 1:** 750 ROYAL OAKS DR
- **CITY:** MONROVIA
- **STATE:** CA
- **ZIP:** 91016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Invizyne Technologies Inc
- **DATE OF NAME CHANGE:** 20240205

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

**June 17, 2025**

**EXOZYMES INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-42204** | **83-4550057** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

**750 Royal Oaks Drive, Suite 106**

**Monrovia, CA 91016**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(626) 415-1488**

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | EXOZ | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 17, 2025, eXoZymes Inc. (the "<u>Company</u>") increased the compensation due to be provided to Michael Heltzen, the Company's Chief Executive Officer, upon the recommendation of the Company's Compensation Committee, as follows: (i) the Company increased Michael Heltzen's base salary to an annualized rate equal to $450,000.00 in the aggregate, (ii) the Company agreed to grant Michael Heltzen options (the "<u>Options</u>") to purchase 235,817 shares of its common stock, par value $0.000001 per share (the "<u>Common Stock</u>"), at an exercise price equal to $12.40 per share of Common Stock, and (iii) the Company agreed to pay Michael Heltzen a one-time bonus equal to $250,000.00 in the aggregate.

The Options would vest over a four (4) year period, in equal quarterly installments at the end of each quarter of the calendar year, and the Options would commence vesting on July 1, 2025. The option expires June 29, 2032.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

**(d)** **Exhibits** 

<u>Exhibits</u> <u>Description of Exhibit</u> <br>104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 20, 2025 | EXOZYMES INC. | EXOZYMES INC. |
|  | By | */s/ Fouad Nawaz* |
|  |  | Fouad Nawaz, |
|  |  | Vice President, Finance |

---